[Evaluation of the efficacy of chelation therapy with deferoxamine in patients with thalassemia major]. 1994

C Rodríguez Galindo, and J J Ortega Aramburu, and J L Alonso, and M Albisu, and J Casaldáliga, and C Díaz de Heredia, and T Olivé, and P Bastida
Servicio de Hematología y Oncología Pediátricas, Hospital Universitario Materno-Infantil Vall d'Hebron, Universidad Autónoma de Barcelona.

BACKGROUND The current treatment of thalassaemia maior (TM) is based on a hypertransfusion regimen, with deferoxamine (DFO) chelation therapy to minimize the consequences of iron overload. To evaluate the long-term efficacy of chelation therapy, a group of 9 patients treated for a period of 9 years was studied. METHODS The mean age of patients at the beginning of chelation therapy was 7 years. The age range at the moment of the study was 11 to 21 years. Pre-transfusion haemoglobin values were maintained above 10 gr/dl. DFO was administered by 10-hour sub-cutaneous infusion, 5 or 6 days a week at a dose of 40 mg/kg. Different iron overload parameters were considered, with special attention to cardiac function, growth and endocrinologic development. Signs of DFO toxicity were also studied. RESULTS The final mean iron elimination rate was 72.6%. One patient died from cardiac haemosiderosis. Eight of the 9 patients showed significant growth impairment and 7, who have attained puberal or post-puberal age, suffer from one or more endocrinologic disorders (6 hypogonadism, 2 diabetes mellitus, 2 hypothyroidism and 1 hypoparathyroidism). The only toxic effect observed was transient crystalline opacity in 2 patients. CONCLUSIONS Despite the early initiation of chelation therapy, TM patients receiving hypertransfusion regimen showed iron overload, with myocardiopathy, growth retardation and several endocrinologic disorders, mainly secondary hypogonadism, glucose metabolism disfunction and primary hypothyroidism.

UI MeSH Term Description Entries
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D003676 Deferoxamine Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form. Desferrioxamine,Deferoxamine B,Deferoxamine Mesilate,Deferoxamine Mesylate,Deferoxamine Methanesulfonate,Deferoximine,Deferrioxamine B,Desferal,Desferioximine,Desferrioxamine B,Desferrioxamine B Mesylate,Desferroxamine,Mesilate, Deferoxamine,Mesylate, Deferoxamine,Mesylate, Desferrioxamine B,Methanesulfonate, Deferoxamine
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006128 Growth Gradual increase in the number, the size, and the complexity of cells of an individual. Growth generally results in increase in ORGAN WEIGHT; BODY WEIGHT; and BODY HEIGHT.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D017086 beta-Thalassemia A disorder characterized by reduced synthesis of the beta chains of hemoglobin. There is retardation of hemoglobin A synthesis in the heterozygous form (thalassemia minor), which is asymptomatic, while in the homozygous form (thalassemia major, Cooley's anemia, Mediterranean anemia, erythroblastic anemia), which can result in severe complications and even death, hemoglobin A synthesis is absent. Anemia, Cooley's,Anemia, Erythroblastic,Anemia, Mediterranean,Hemoglobin F Disease,Thalassemia Major,Thalassemia Minor,Erythroblastic Anemia,Mediterranean Anemia,Microcytemia, beta Type,Thalassemia Intermedia,Thalassemia Major (beta-Thalassemia Major),Thalassemia Minor (beta-Thalassemia Minor),Thalassemia, beta Type,beta Thalassemia,Anemia, Cooley,Anemia, Cooleys,Anemias, Erythroblastic,Anemias, Mediterranean,Cooley's Anemia,Disease, Hemoglobin F,Intermedia, Thalassemia,Intermedias, Thalassemia,Major, Thalassemia (beta-Thalassemia Major),Majors, Thalassemia (beta-Thalassemia Major),Mediterranean Anemias,Microcytemias, beta Type,Minor, Thalassemia (beta-Thalassemia Minor),Minors, Thalassemia (beta-Thalassemia Minor),Thalassemia Intermedias,Thalassemia Major (beta Thalassemia Major),Thalassemia Majors (beta-Thalassemia Major),Thalassemia Minor (beta Thalassemia Minor),Thalassemia Minors (beta-Thalassemia Minor),Thalassemia, beta,Thalassemias, beta,Thalassemias, beta Type,Type Microcytemia, beta,Type Microcytemias, beta,Type Thalassemia, beta,Type Thalassemias, beta,beta Thalassemias,beta Type Microcytemia,beta Type Microcytemias,beta Type Thalassemia,beta Type Thalassemias

Related Publications

C Rodríguez Galindo, and J J Ortega Aramburu, and J L Alonso, and M Albisu, and J Casaldáliga, and C Díaz de Heredia, and T Olivé, and P Bastida
January 2006, Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance,
C Rodríguez Galindo, and J J Ortega Aramburu, and J L Alonso, and M Albisu, and J Casaldáliga, and C Díaz de Heredia, and T Olivé, and P Bastida
April 1978, The Journal of pediatrics,
C Rodríguez Galindo, and J J Ortega Aramburu, and J L Alonso, and M Albisu, and J Casaldáliga, and C Díaz de Heredia, and T Olivé, and P Bastida
February 2013, Blood cells, molecules & diseases,
C Rodríguez Galindo, and J J Ortega Aramburu, and J L Alonso, and M Albisu, and J Casaldáliga, and C Díaz de Heredia, and T Olivé, and P Bastida
January 1985, Medicina,
C Rodríguez Galindo, and J J Ortega Aramburu, and J L Alonso, and M Albisu, and J Casaldáliga, and C Díaz de Heredia, and T Olivé, and P Bastida
January 2014, Hemoglobin,
C Rodríguez Galindo, and J J Ortega Aramburu, and J L Alonso, and M Albisu, and J Casaldáliga, and C Díaz de Heredia, and T Olivé, and P Bastida
September 1988, Transfusion medicine reviews,
C Rodríguez Galindo, and J J Ortega Aramburu, and J L Alonso, and M Albisu, and J Casaldáliga, and C Díaz de Heredia, and T Olivé, and P Bastida
January 2010, Acta haematologica,
C Rodríguez Galindo, and J J Ortega Aramburu, and J L Alonso, and M Albisu, and J Casaldáliga, and C Díaz de Heredia, and T Olivé, and P Bastida
January 2013, Hematology (Amsterdam, Netherlands),
C Rodríguez Galindo, and J J Ortega Aramburu, and J L Alonso, and M Albisu, and J Casaldáliga, and C Díaz de Heredia, and T Olivé, and P Bastida
June 2009, JPMA. The Journal of the Pakistan Medical Association,
C Rodríguez Galindo, and J J Ortega Aramburu, and J L Alonso, and M Albisu, and J Casaldáliga, and C Díaz de Heredia, and T Olivé, and P Bastida
April 1995, The New England journal of medicine,
Copied contents to your clipboard!